Prima BioMed - Stock Price History | IMMP

Historical daily share price chart and data for Prima BioMed since 2021 adjusted for splits. The latest closing stock price for Prima BioMed as of October 27, 2021 is 4.40.
  • The all-time high Prima BioMed stock closing price was 24.00 on April 20, 2012.
  • The Prima BioMed 52-week high stock price is 7.95, which is 80.7% above the current share price.
  • The Prima BioMed 52-week low stock price is 1.65, which is 62.5% below the current share price.
  • The average Prima BioMed stock price for the last 52 weeks is 3.43.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Prima BioMed Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 1.6798 1.8500 5.6900 0.6700 3.1400 75.42%
2019 1.8493 2.0400 2.5700 1.2700 1.7900 -2.72%
2018 2.3906 1.6400 3.9000 1.6400 1.8400 17.20%
2017 2.1285 2.5300 2.9300 1.3200 1.5700 -32.91%
2016 3.0369 3.9333 3.9333 2.1000 2.3400 -38.42%
2015 3.8315 2.5000 19.7000 1.6337 3.8000 70.12%
2014 3.6971 3.7033 5.6667 2.2337 2.2337 -39.08%
2013 7.9732 12.3330 13.1667 2.8000 3.6667 -67.93%
2012 14.8844 23.3333 24.0000 10.5000 11.4333 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.398B $0.003B
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86